SynthesisTremor and other hyperkinetic movements (New York, N.Y.)2026
Spectrum of Movement Disorders in Hematological Malignancies: A Comprehensive Systematic Review of Clinical Phenotypes, Mechanisms, and Outcomes.
Synthesis in Tremor and other hyperkinetic movements (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Movement disorders associated with hematologic malignancies remain incompletely defined. This review synthesized published articles to clarify clinical patterns, mechanisms, and outcomes across hematologic malignancies. Methods: A PRISMA-compliant systematic search of PubMed, Embase, Scopus, and Google Scholar was conducted to identify reports describing movement disorders associated with hematologic malignancies. Eligible reports were screened according to predefined criteria, and data were extracted on demographics, hematologic diagnosis, central nervous system (CNS) involvement, movement-disorder phenotype, investigative findings, treatments administered, and neurological outcomes. Results: A total of 252 cases were included: 152 lymphoid, 78 myeloid, and 22 plasma-cell neoplasms. Lymphoid malignancies most commonly presented with cerebellar ataxia (55.3 percent), followed by parkinsonism (18.4 percent) and chorea (11.8 percent), with CNS involvement frequent, including infiltration (33.6 percent) and immune-mediated injury (30.3 percent). Myeloid disorders showed a predominantly hyperkinetic profile, especially generalized chorea (41 percent) and hemichorea or hemiballismus (17.9 percent), while structural CNS disease was rare (2.6 percent) and most cases reflected systemic or treatment-related mechanisms. Plasma-cell neoplasms were characterized mainly by parkinsonism (45.5 percent) and cerebellar syndromes (27.3 percent). Neurological improvement occurred in most patients, particularly after treatment of underlying hematologic disorder. In a cohort of 232 CNS lymphoma patients, prodromal neuropsychiatric features occurred in 9 percent, parkinsonism in 25 percent of those, and 80 percent improved following lymphoma-directed therapy. Conclusions: Movement disorders in hematologic cancers show distinct, disease-specific profiles, with cerebellar, hyperkinetic, and parkinsonian patterns corresponding to lymphoid, myeloid, and plasma-cell neoplasms. CNS involvement mechanisms differ, providing essential diagnostic and therapeutic guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.